ALOX5 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, they showed that in vivo administration of PD146176 (an Alox15 inhibitor) and/or zileuton (an Alox5 inhibitor) can diminish the relapse of CML disease in WT CML model mice (108, 109).